Skip to main content
Top
Published in: International Journal of Hematology 4/2012

01-10-2012 | Original Article

Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis

Authors: Yuhei Kamada, Mamiko Sakata-Yanagimoto, Masashi Sanada, Aiko Sato-Otsubo, Terukazu Enami, Kazumi Suzukawa, Naoki Kurita, Hidekazu Nishikii, Yasuhisa Yokoyama, Yasushi Okoshi, Yuichi Hasegawa, Seishi Ogawa, Shigeru Chiba

Published in: International Journal of Hematology | Issue 4/2012

Login to get access

Abstract

Single-nucleotide polymorphism genotyping microarray (SNP array) analysis provides detailed information on chromosomal copy number aberrations. To obtain detailed information on genomic abnormalities related to pathogenesis or prognosis of multiple myeloma (MM), we performed 250K SNP array analysis in 39 MM patients and 11 cell lines. We identified an accumulation of deletions and uniparental disomies at 22q12.1. Among the hyperdiploid MM cases, chromosomal imbalance at this locus was associated with poor prognosis. On sequencing, we also found a mutation in the seizure-related 6 homolog (mouse)-like (SEZ6L) gene located at ch.22q12.1 in an MM cell line, NOP1. We further found isolated deletions in 17 genes, five of which are known tumor suppressor genes. Of these, deletion of protein tyrosine phosphatase, receptor type D (PTPRD) was found in three samples, including two patients. Consistent with previous reports, non-hyperdiploid MM, deletion of 13q (del13q) and gain of 1q in non-hyperdiploid MMs were predictive of poor prognosis (p = 0.039, p = 0.049, and p = 0.013, respectively). However, our analysis revealed that unless accompanied by gain of 1q, the prognosis of non-hyperdiploid MM was as good as that of hyperdiploid MM. Thus, SNP array analysis provides significant information useful to understanding the pathogenesis and prognosis of MM.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Chng WJ, et al. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571–96.PubMedCrossRef Chng WJ, et al. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571–96.PubMedCrossRef
3.
go back to reference Largo C, et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica. 2007;92(6):795–802.PubMedCrossRef Largo C, et al. Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica. 2007;92(6):795–802.PubMedCrossRef
4.
go back to reference Flactif M, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9(12):2109–14.PubMed Flactif M, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9(12):2109–14.PubMed
5.
go back to reference Chang H, et al. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia. 1999;13(1):105–9.PubMedCrossRef Chang H, et al. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia. 1999;13(1):105–9.PubMedCrossRef
6.
go back to reference Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333–8.PubMedCrossRef Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333–8.PubMedCrossRef
7.
go back to reference Walker BA, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–65.PubMedCrossRef Walker BA, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56–65.PubMedCrossRef
8.
go back to reference Walker BA, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006;108(5):1733–43.PubMedCrossRef Walker BA, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006;108(5):1733–43.PubMedCrossRef
9.
go back to reference Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75.PubMedCrossRef Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75.PubMedCrossRef
10.
go back to reference Zojer N, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95(6):1925–30.PubMed Zojer N, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95(6):1925–30.PubMed
11.
12.
go back to reference Sanada M, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–8.PubMedCrossRef Sanada M, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460(7257):904–8.PubMedCrossRef
13.
go back to reference Agnelli L, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48(7):603–14.PubMedCrossRef Agnelli L, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48(7):603–14.PubMedCrossRef
14.
go back to reference Mullighan CG, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–64.PubMedCrossRef Mullighan CG, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–64.PubMedCrossRef
15.
go back to reference Nannya Y, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005;65(14):6071–9.PubMedCrossRef Nannya Y, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005;65(14):6071–9.PubMedCrossRef
16.
go back to reference Shaffer LG (2009) An International System for Human Cytogenetic Nomenclature 2009. Shaffer LG (2009) An International System for Human Cytogenetic Nomenclature 2009.
17.
go back to reference Nishioka M, et al. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene. 2000;19(54):6251–60.PubMedCrossRef Nishioka M, et al. Identification of a 428-kb homozygously deleted region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line. Oncogene. 2000;19(54):6251–60.PubMedCrossRef
18.
19.
go back to reference Gorlov IP, et al. Seizure 6-like (SEZ6L) gene and risk for lung cancer. Cancer Res. 2007;67(17):8406–11.PubMedCrossRef Gorlov IP, et al. Seizure 6-like (SEZ6L) gene and risk for lung cancer. Cancer Res. 2007;67(17):8406–11.PubMedCrossRef
20.
go back to reference Kang GH, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 2008;88(2):161–70.PubMedCrossRef Kang GH, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 2008;88(2):161–70.PubMedCrossRef
21.
go back to reference Bleeker FE, et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Hum Mutat. 2009;30(2):E451–9.PubMedCrossRef Bleeker FE, et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Hum Mutat. 2009;30(2):E451–9.PubMedCrossRef
22.
go back to reference Bakkus MH, et al. Amplification of the c-myc and the pvt-like region in human multiple myeloma. Oncogene. 1990;5(9):1359–64.PubMed Bakkus MH, et al. Amplification of the c-myc and the pvt-like region in human multiple myeloma. Oncogene. 1990;5(9):1359–64.PubMed
23.
go back to reference Broustas CG, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16(11):2939–48.PubMedCrossRef Broustas CG, et al. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010;16(11):2939–48.PubMedCrossRef
24.
go back to reference Sahab ZJ, et al. Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26. J Cancer. 2010;1:14–22.PubMedCrossRef Sahab ZJ, et al. Tumor Suppressor RARRES1 Regulates DLG2, PP2A, VCP, EB1, and Ankrd26. J Cancer. 2010;1:14–22.PubMedCrossRef
25.
go back to reference Tada M, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010;101(5):1261–9.PubMedCrossRef Tada M, et al. Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci. 2010;101(5):1261–9.PubMedCrossRef
26.
go back to reference Vazquez A, et al. A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer. 2011;128(19):2335–43. Vazquez A, et al. A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer. 2011;128(19):2335–43.
27.
go back to reference Zhao Y, et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci USA. 2010;107(6):2592–7.PubMedCrossRef Zhao Y, et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci USA. 2010;107(6):2592–7.PubMedCrossRef
28.
go back to reference Cavalli LR, et al. Frequent Loss of the BLID Gene in Early-Onset Breast Cancer. Cytogenet Genome Res. 2011;135(1):19–24.PubMedCrossRef Cavalli LR, et al. Frequent Loss of the BLID Gene in Early-Onset Breast Cancer. Cytogenet Genome Res. 2011;135(1):19–24.PubMedCrossRef
29.
go back to reference Smadja NV, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229–38.PubMedCrossRef Smadja NV, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229–38.PubMedCrossRef
30.
go back to reference Fonseca R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546–58.PubMedCrossRef Fonseca R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546–58.PubMedCrossRef
31.
go back to reference Seong C, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101(1):189–94.PubMedCrossRef Seong C, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101(1):189–94.PubMedCrossRef
32.
go back to reference Dewald GW, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106(10):3553–8.PubMedCrossRef Dewald GW, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106(10):3553–8.PubMedCrossRef
33.
go back to reference Fassas AB, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118(4):1041–7.PubMedCrossRef Fassas AB, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118(4):1041–7.PubMedCrossRef
34.
go back to reference Leone PE, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008;14(19):6033–41.PubMedCrossRef Leone PE, et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008;14(19):6033–41.PubMedCrossRef
35.
go back to reference Fonseca R, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40.PubMedCrossRef Fonseca R, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40.PubMedCrossRef
36.
go back to reference Zhan F, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995–5001.PubMedCrossRef Zhan F, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995–5001.PubMedCrossRef
37.
go back to reference Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl 1):117–26.PubMedCrossRef Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl 1):117–26.PubMedCrossRef
38.
go back to reference Willis TG, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91(6):1873–81.PubMed Willis TG, et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91(6):1873–81.PubMed
39.
go back to reference Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67(6):2632–42.PubMedCrossRef Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67(6):2632–42.PubMedCrossRef
40.
go back to reference Kohno T, et al. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010;49(4):342–52.PubMed Kohno T, et al. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer. 2010;49(4):342–52.PubMed
41.
go back to reference Mokarram P, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.PubMedCrossRef Mokarram P, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.PubMedCrossRef
42.
go back to reference Chan TA, Heguy A. The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. Cell Cycle. 2009;8(19):3063–4.PubMedCrossRef Chan TA, Heguy A. The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. Cell Cycle. 2009;8(19):3063–4.PubMedCrossRef
43.
go back to reference Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42(11):1574–80.PubMedCrossRef Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42(11):1574–80.PubMedCrossRef
44.
go back to reference French JD, Tschumper RC, Jelinek DF. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia. 2002;16(6):1189–96.PubMedCrossRef French JD, Tschumper RC, Jelinek DF. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia. 2002;16(6):1189–96.PubMedCrossRef
45.
go back to reference Jenner MW, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9):3291–300.PubMedCrossRef Jenner MW, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9):3291–300.PubMedCrossRef
46.
go back to reference Takada S, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol. 2005;75(6):505–10.PubMedCrossRef Takada S, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol. 2005;75(6):505–10.PubMedCrossRef
47.
go back to reference de Carvalho F, et al. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8):1985–91.PubMedCrossRef de Carvalho F, et al. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8):1985–91.PubMedCrossRef
48.
go back to reference Siwarski D, et al. Structure and expression of the c-Myc/Pvt 1 megagene locus. Curr Top Microbiol Immunol. 1997;224:67–72.PubMedCrossRef Siwarski D, et al. Structure and expression of the c-Myc/Pvt 1 megagene locus. Curr Top Microbiol Immunol. 1997;224:67–72.PubMedCrossRef
49.
go back to reference Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst). 2006;5(9–10):1213–24.CrossRef Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst). 2006;5(9–10):1213–24.CrossRef
50.
go back to reference Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467–72.PubMedCrossRef Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467–72.PubMedCrossRef
Metadata
Title
Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis
Authors
Yuhei Kamada
Mamiko Sakata-Yanagimoto
Masashi Sanada
Aiko Sato-Otsubo
Terukazu Enami
Kazumi Suzukawa
Naoki Kurita
Hidekazu Nishikii
Yasuhisa Yokoyama
Yasushi Okoshi
Yuichi Hasegawa
Seishi Ogawa
Shigeru Chiba
Publication date
01-10-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-012-1171-1

Other articles of this Issue 4/2012

International Journal of Hematology 4/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine